Browsing by Author "Doubova, Svetlana, V"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    COVID-19 and resilience of healthcare systems in ten countries
    (2022) Arsenault, Catherine; Gage, Anna; Kim, Min Kyung; Kapoor, Neena R.; Akweongo, Patricia; Amponsah, Freddie; Aryal, Amit; Asai, Daisuke; Awoonor-Williams, John Koku; Ayele, Wondimu; Bedregal, Paula; Doubova, Svetlana, V; Dulal, Mahesh; Gadeka, Dominic Dormenyo; Gordon-Strachan, Georgiana; Mariam, Damen Haile; Hensman, Dilipkumar; Joseph, Jean Paul; Kaewkamjornchai, Phanuwich; Eshetu, Munir Kassa; Gelaw, Solomon Kassahun; Kubota, Shogo; Leerapan, Borwornsom; Margozzini, Paula; Mebratie, Anagaw Derseh; Mehata, Suresh; Moshabela, Mosa; Mthethwa, Londiwe; Nega, Adiam; Oh, Juhwan; Park, Sookyung; Passi-Solar, Alvaro; Perez-Cuevas, Ricardo; Phengsavanh, Alongkhone; Reddy, Tarylee; Rittiphairoj, Thanitsara; Sapag, Jaime C.; Thermidor, Roody; Tlou, Boikhutso; Guinez, Francisco Valenzuela; Bauhoff, Sebastian; Kruk, Margaret E.
    Declines in health service use during the Coronavirus Disease 2019 (COVID-19) pandemic could have important effects on population health. In this study, we used an interrupted time series design to assess the immediate effect of the pandemic on 31 health services in two low-income (Ethiopia and Haiti), six middle-income (Ghana, Lao People's Democratic Republic, Mexico, Nepal, South Africa and Thailand) and high-income (Chile and South Korea) countries. Despite efforts to maintain health services, disruptions of varying magnitude and duration were found in every country, with no clear patterns by country income group or pandemic intensity. Disruptions in health services often preceded COVID-19 waves. Cancer screenings, TB screening and detection and HIV testing were most affected (26-96% declines). Total outpatient visits declined by 9-40% at national levels and remained lower than predicted by the end of 2020. Maternal health services were disrupted in approximately half of the countries, with declines ranging from 5% to 33%. Child vaccinations were disrupted for shorter periods, but we estimate that catch-up campaigns might not have reached all children missed. By contrast, provision of antiretrovirals for HIV was not affected. By the end of 2020, substantial disruptions remained in half of the countries. Preliminary data for 2021 indicate that disruptions likely persisted. Although a portion of the declines observed might result from decreased needs during lockdowns (from fewer infectious illnesses or injuries), a larger share likely reflects a shortfall of health system resilience. Countries must plan to compensate for missed healthcare during the current pandemic and invest in strategies for better health system resilience for future emergencies.
  • No Thumbnail Available
    Item
    Data sources for drug utilization research in Latin American countries-A cross-national study: DASDUR-LATAM study
    (2022) Lopes, Luciane C.; Salas, Maribel; Serpa Osorio-de-Castro, Claudia Garcia; Leal, Lisiane Freitas; Doubova, Svetlana, V; Canas, Martin; Dreser, Anahi; Acosta, Angela; Baldoni, Andre Oliveira; Bergamaschi, Cristiane de Cassia; Mota, Daniel Marques; Gomez-Galicia, Diana L.; Sepulveda-Viveros, Dino; Delgado, Edgard Narvaez; Lima, Elisangela da Costa; Chandia, Felipe Vera; Ferre, Felipe; Marin, Gustavo H.; Olmos, Ismael; Zimmermann, Ivan R.; Fulone, Izabela; Roldan-Saelzer, Juan; Sanchez-Salgado, Juan Carlos; Castro-Pastrana, Lucila, I; Carneiro de Souza, Luiz Jupiter; Beltran, Manuel Machado; Silva, Marcus Tolentino; Mena, Maria Belen; de Franca Fonteles, Marta Maria; Urtasun, Martin A.; Tarapues, Monica; Hernandez, Patricia Granja; Medero, Natalia; Herrera-Comoglio, Raquel; Barberato-Filho, Silvio; Galvao, Tais Freire; Luiza, Vera Lucia; Santa-Ana-Tellez, Yared; Rodriguez-Tanta, Yesenia; Elseviers, Monique
    Purpose Drug utilization research (DUR) contributes to inform policymaking and to strengthen health systems. The availability of data sources is the first step for conducting DUR. However, documents that systematize these data sources in Latin American (LatAm) countries are not known. We compiled the potential data sources for DUR in the LatAm region. Methods A network of DUR experts from nine LatAm countries was assembled and experts conducted: (i) a website search of the government, academic, and private health institutions; (ii) screening of eligible data sources, and (iii) liaising with national experts in pharmacoepidemiology (via an online survey). The data sources were characterized by accessibility, geographic granularity, setting, sector of the data, sources and type of the data. Descriptive analyses were performed. Results We identified 125 data sources for DUR in nine LatAm countries. Thirty-eight (30%) of them were publicly and conveniently available; 89 (71%) were accessible with limitations, and 18 (14%) were not accessible or lacked clear rules for data access. From the 125 data sources, 76 (61%) were from the public sector only; 46 (37%) were from pharmacy records; 43 (34%) came from ambulatory settings and; 85 (68%) gave access to individual patient-level data. Conclusions Although multiple sources for DUR are available in LatAm countries, the accessibility is a major challenge. The procedures for accessing DUR data should be transparent, feasible, affordable, and protocol-driven. This inventory could permit a comparison of drug utilization between countries identifying potential medication-related problems that need further exploration.